You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
Register for free to read this article
As a service to the community, this article is available for free. Existing users log in.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Early signs of dementia
There is currently no cure for Alzheimer's disease. One of the reasons could be that interventions start too late, when there is already irreversible damage to the brain. Developing a biomarker that would help to effectively start therapy at very early stages of the disease is thus of high interest. Kunz et al. studied neural correlates of spatial navigation in the entorhinal cortex in control study participants and individuals at risk of developing Alzheimer's. The at-risk group showed a different brain signal many decades before the onset of the disease, and they navigated differently in a virtual environment.
Science, this issue p. 430
Abstract
Alzheimer’s disease (AD) manifests with memory loss and spatial disorientation. AD pathology starts in the entorhinal cortex, making it likely that local neural correlates of spatial navigation, particularly grid cells, are impaired. Grid-cell–like representations in humans can be measured using functional magnetic resonance imaging. We found that young adults at genetic risk for AD (APOE-ε4 carriers) exhibit reduced grid-cell–like representations and altered navigational behavior in a virtual arena. Both changes were associated with impaired spatial memory performance. Reduced grid-cell–like representations were also related to increased hippocampal activity, potentially reflecting compensatory mechanisms that prevent overt spatial memory impairment in APOE-ε4 carriers. Our results provide evidence of behaviorally relevant entorhinal dysfunction in humans at genetic risk for AD, decades before potential disease onset.
